- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Targeted Therapies Explored in Small Cell Lung Cancer
November 11th 2013, 7:40am
PER® New York Lung Cancer Symposium
While targeted and immunotherapy drugs have recently shown promise in non-small cell lung cancer (NSCLC), similar developments in small cell lung cancer (SCLC) have not materialized.
Dr. Rizvi on PD-1 and PD-L1 Inhibitors in Lung Cancer
November 10th 2013, 10:00am
PER® New York Lung Cancer Symposium
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.
Dr. Shaw on Monitoring Crizotinib-Related Side Effects
November 10th 2013, 9:58am
PER® New York Lung Cancer Symposium
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses monitoring adverse events associated with crizotinib when treating patients with ALK-positive lung cancer
NY Symposium Tackles Emerging Agents, Pressing Questions in Lung Cancer
November 8th 2013, 2:53pm
PER® New York Lung Cancer Symposium
Leaders in thoracic medical oncology from major cancer centers will come together Saturday to discuss advances in the field of lung cancer treatment during the 8th Annual New York Lung Cancer Symposium® in New York City.
Dovitinib Fails as Third-Line Option in Kidney Cancer
October 3rd 2013, 10:25am
Dovitinib failed to meet the primary endpoint of improving progression-free survival versus sorafenib (Nexavar) in patients with heavily pretreated progressive renal cell carcinoma
Biomarkers Predict Prognosis for Patients With mCRPC
October 3rd 2013, 8:46am
A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with metastatic castration-resistant prostate cancer
Trebananib Shows Promise in Recurrent Platinum-Sensitive Ovarian Cancer
October 3rd 2013, 8:17am
Trebananib added to paclitaxel significantly improved progression-free survival in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA-1 trial.
Dr. Schmidinger on Targeted Agent Side Effects in RCC
October 2nd 2013, 10:23am
Manuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted agents in renal cell cancer, including hypertension, diarrhea, and hand-foot syndrome.
Dr. Yoshino on U3-1565 and TAS-102 in Colorectal Cancer
October 2nd 2013, 8:37am
Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses U3-1565 and TAS-102, two agents used to treat colorectal cancer.
Pooled Analysis Reinforces Long-Term Survival Benefit With Ipilimumab
October 2nd 2013, 6:52am
Results from a pooled analysis of data from 12 studies has demonstrated a long-term survival benefit that extends through at least 10 years for patients with advanced melanoma treated with ipilimumab.
Dr. Crinò on Crizotinib in ALK-Positive NSCLC
October 1st 2013, 10:41am
Lucio Crinò, MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer
Additional OS and PFS Benefits Seen With Aflibercept in Post-Hoc VELOUR Analysis
October 1st 2013, 8:02am
A post-hoc analysis of the VELOUR trial demonstrated additional improvements in both overall survival and progression-free survival in favor of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer
Dr. Hudis on BOLERO-3 Trial Biomarker Observations
October 1st 2013, 7:59am
Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, attending physician, Memorial Sloan-Kettering Cancer Center, comments on exploratory biomarker observations from the BOLERO-3 trial.
Dual HER2 Blockade Less Effective in PI3KCA-Mutant Breast Cancer
October 1st 2013, 7:33am
Breast cancer patients with PI3KCA mutations are less likely to achieve a pathological complete response from dual HER2 blockade in the neoadjuvant setting.
Enzalutamide Plus Abiraterone May Have Higher Response Rate in mCRPC Than Either Agent Alone
October 1st 2013, 7:08am
Co-targeting metastatic castrate resistant prostate cancer with the combination of enzalutamide plus abiraterone acetate may circumvent the compensatory mechanisms observed with either agent alone and lead to more profound suppression of androgen signaling.
Dr. Grünwald on Dovitinib Versus Sorafenib in mRCC
September 30th 2013, 4:44pm
Viktor Grünwald, MD, PhD, from the Hannover Medical School, discusses a phase III trial that compared dovitinib to sorafenib for patients with mRCC following prior treatment with one VEGF inhibitor and one mTOR inhibitor.
Dr. Camidge on a Phase I Study With AZD9291 in NSCLC
September 30th 2013, 10:03am
D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses a phase I study looking at AZD9291 in patients with non-small cell lung cancer.
Novel ALK Inhibitor Shows Promise Against Brain Metastasis in NSCLC
September 30th 2013, 9:13am
The first-in-human phase I/II dose-finding study of a novel ALK/EGFR inhibitor called AP26113 demonstrated promising results in both crizotinib-resistant and crizotinib-naïve patients with non-small cell lung cancer.
Survival Benefit Observed With Cetuximab in RAS Wild-Type Colorectal Cancer
September 30th 2013, 8:28am
Cetuximab plus FOLFIRI may offer a survival advantage over FOLFIRI plus bevacizumab in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer who do not have RAS mutations.
Dr. George on Critical Clinical Trials in Kidney Cancer
September 30th 2013, 8:11am
Daniel J. George, MD, Director, GU Oncology, Duke Cancer Institute, discusses critical phase III clinical trials in metastatic renal cell carcinoma.